Advertisement
Under RainDance's Early Access Partner program, RainDance will provide itsnew RDT 1000 and expert training to the GC, along with customized PCR primerlibraries to selectively amplify loci of interest for their researchinitiatives.
Advertisement
Elaine Mardis, Ph.D., Co-Director of The Genome Center, said GCresearchers "will be applying the platform in our large-scale targetedsequencing studies and are enthusiastic about reporting their experiences andresults."
"If the technology delivers as promised, RainDance Technology stands tosignificantly advance the art of targeted sequencing," Dr. Mardis said.
"As a leader in advancing genome sequencing and its application to humanhealth, we're very excited about the participation of the GC in our EarlyPartnership Program. Their input and experience will be invaluable as weintroduce the RainStorm platform to the world's DNA sequencing market," saidChris McNary, President and Chief Executive Officer of RainDance Technologies.
"RainDance plans to commercially launch the RainDance platform in thefirst quarter of 2009," McNary added.
The RDT 1000 and Sequence Enrichment application utilize RainDance'sbreakthrough RainStorm droplet-based technology platform. The simplicity,speed, and minute volume of the technology are designed to maximize theefficiency of next-generation DNA sequencing workflows. The RDT 1000 generatespicoliter volume PCR reactions at the rate of 10 million discrete reactionsper hour. The high-speed sample processing is further enhanced by the factthat the Sequence Enrichment application utilizes a library of PCR primers indroplets enabling the amplification of hundreds to thousands of genomic lociin a single tube. The RainStorm format avoids the limitations of traditionalmultiplex hybridization and amplification technologies. RainDance's solutionminimizes process-induced bias or error and requires only a few micrograms ofgenomic DNA.
About RainDance Technologies, Inc.
RainDance Technologies Inc. is a provider of innovative microdroplet-basedsolutions for human health and disease research. The speed and simplicity ofthe company's exciting new technology platform enable researchers to designexperiments in ways that were previously unaffordable or unimaginable. Thecompany's technology produces picoliter-volume droplets at a rate of 10million per hour. Each droplet is the functional equivalent of an individualtest tube and can contain a single molecule, reaction, or cell. This versatiletechnology can adapt proven assays for high-speed workflows with minimizedprocess-induced bias or error.
RainDance's initial application will focus on the targeted resequencing ofthe human genome -- one of the fastest-growing segments of the $1 billion DNAsequencing market. This application will enable the high-resolution analysisof genetic variation between individuals and populations at a level unmatchedby current methodology.
RainDance was founded in 2004 by scientists from Harvard University; theMedical Research Centre in Cambridge, England and the ESPCI in Paris.
For more information, please visit http://www.raindancetech.com.Available Topic Expert(s): For information on the listed expert(s), clickappropriate link.Steven Beckerhttps://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=78145
SOURCE RainDance Technologies, Inc.
